Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth

Pancreas

Volumn 36, Issue 4, 2008, Pages 353-362

  Funahashi, Hitoshi ^a   Satake, Makoto ^a   Hasan, Sascha ^a   Sawai, Hirozumi ^b   Newman, Robert A ^c   Reber, Howard A ^a   Hines, Oscar J ^a   Eibl, Guido ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Cyclooxygenase; EP receptors; Fatty acids; Pancreatic cancer; Prostaglandin

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E3; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RECEPTOR BINDING; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CYCLIC AMP; CYCLOOXYGENASE 2; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; MICE; MODELS, ANIMAL; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RNA, NEOPLASM; TRANSFECTION;

EID: 42549119900     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31815ccc44     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Hochster HS, Haller DG, de GA, et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006;107:676-685.
3. Granados S, Quiles JL, Gil A, et al. Dietary lipids and cancer. Nutr Hosp. 2006;21(suppl 2):42-54.
4. Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother. 2006;60:502-507.
5. Larsson SC, Kumlin M, Ingelman-Sundberg M, et al. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. 2004;79:935-945.
6. Smith WL. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol. 2005;17:174-182.
7. Kato T, Hancock RL, Mohammadpour H, et al. Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice. Cancer Lett. 2002;187:169-177.
8. Kelavkar UP, Hutzley J, Dhir R, et al. Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia. 2006;8:112-124.
9. Kobayashi N, Barnard RJ, Henning SM, et al. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006;12:4662-4670.
10. Reddy BS, Patlolla JM, Simi B, et al. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer Res. 2005;65:8022-8027.
11. Wu M, Harvey KA, Ruzmetov N, et al. Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway. Int J Cancer. 2005;117:340-348.
12. Xia S, Lu Y, Wang J, et al. Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A. 2006;103:12499-12504.
13. Yee LD, Young DC, Rosol TJ, et al. Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. J Nutr. 2005;135:983-988.
14. Gregor JI, Heukamp I, Kilian M, et al. Does enteral nutrition of dietary polyunsaturated fatty acids promote oxidative stress and tumour growth in ductal pancreatic cancer? Experimental trial in Syrian hamster. Prostaglandins Leukot Essent Fatty Acids. 2006;74:67-74.
15. Heukamp I, Gregor JI, Kilian M, et al. Influence of different dietary fat intake on liver metastasis and hepatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology. 2006;6:96-102.
16. Merendino N, Loppi B, D'Aquino M, et al. Docosahexaenoic acid induces apoptosis in the human PaCa-44 pancreatic cancer cell line by active reduced glutathione extrusion and lipid peroxidation. Nutr Cancer. 2005;52:225-233.
17. Shirota T, Haji S, Yamasaki M, et al. Apoptosis in human pancreatic cancer cells induced by eicosapentaenoic acid. Nutrition. 2005;21:1010-1017.
18. Eibl G, Takata Y, Boros LG, et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res. 2005;65:982-990.
19. Sawai H, Okada Y, Kazanjian K, et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res. 2005;65:11536-11544.
20. Yang P, Felix E, Madden T, et al. Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal Biochem. 2002;308:168-177.
21. Yang P, Chan D, Felix E, et al. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids. 2006;75:385-395.
22. Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 2005;65:2738-2745.
23. Eibl G, Bruemmer D, Okada Y, et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 2003;306:887-897.
24. Sugimoto Y, Narumiya S. Prostaglandin E receptor. J Biol Chem. 2007;282(16):11613-11617.
25. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci. 2003;74:143-153.
26. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296:1885-1899.
27. Chen YQ, Berquin IM, Daniel LW, et al. Omega-3 fatty acids and cancer risk. JAMA. 2006;296:282.
28. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA. 2006;295:403-415.
29. Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr. 2004;134:3427S-3430S.
30. Barber MD, Fearon KC, Tisdale MJ, et al. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer. 2001;40:118-124.
31. Moses AW, Slater C, Preston T, et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer. 2004;90:996-1002.
32. Calviello G, Di NF, Gragnoli S, et al. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis. 2004;25:2303-2310.
33. Horia E, Watkins BA. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis. 2007;28:809-815.
34. Hughes-Fulford M, Chen Y, Tjandrawinata RR. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis. 2001;22:701-707.
35. Hughes-Fulford M, Tjandrawinata RR, Li CF, et al. Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells. Carcinogenesis. 2005;26:1520-1526.
36. Abedin M, Lim J, Tang TB, et al. N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-gamma pathways. Circ Res. 2006;98:727-729.
37. Sun H, Berquin IM, Edwards IJ. Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res. 2005;65:4442-4447.
38. Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999;3:397-403.
39. Eibl G, Wente MN, Reber HA, et al. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun. 2001;287:522-529.
40. Krey G, Braissant O, L'Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997;11:779-791.
41. Yang P, Chan D, Felix E, et al. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res. 2004;45:1030-1039.
42. Fujino H, Regan JW. EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol Pharmacol. 2006;69:5-10.